Claims for Patent: 10,016,385

Summary for Patent: 10,016,385

Title:	Method for extending lifespan delaying the onset of age-related disease
Abstract:	A method and composition for extending the lifespan of an individual and delaying the onset of age-related disease is provided. The method includes the administration of an effective dose of oxaloacetate, wherein the oxaloacetate acts to mimic the cellular conditions obtained under caloric restriction to provide similar benefits. The invention further includes methods and compositions for reducing the incidence or treatment of cancer. Compositions and methods for reducing body fat by administering an effective amount of oxaloacetate are likewise provided. Compositions for DNA repair in UV damaged cells is provided are also provided. Similarly, a method for treating a hang-over comprising administering an effective amount of oxaloacetate is disclosed.
Inventor(s):	B. Cash; Alan (San Diego, CA)
Assignee:
Application Number:	11/792,703
Patent Claims:	1. A method for treating a disease punitively affected by calorie restriction comprising administering to a subject in need thereof a pharmaceutically effective amount of a composition comprising a compound selected from the group consisting of oxaloacetate, oxaloacetic acid, and oxaloacetate salt for treating a disease punitively affected by calorie restriction, wherein the disease is cancer. 2. The method of claim 1, further comprising administering a chemotherapeutic agent to the subject. 3. The method of claim 2, wherein said chemotherapeutic agent is administered prior to administering said compound. 4. The method of claim 2, wherein said chemotherapeutic agent is administered after administering said compound. 5. The method of claim 2, wherein said chemotherapeutic agent is administered substantially contemporaneously with said compound. 6. The method of claim 2, wherein the chemotherapeutic agent is cyclophosphamide, chlorambucil, melphalan, estramustine, iphosphamide, prednimustin, busulphan, thiotepa, carmustine, lomustine, methotrexate, azathioprine, mercaptopurine, thioguanine, cytarabine, fluorouracil, vinblastine, vincristine, vindesine, etoposide, teniposide, dactinomycin, doxorubicin, daunorubicin, epirubicin, bleomycin, mitomycin, cisplatin, carboplatin, procarbazine, amacrine, mitoxantrone, tamoxifen, nilutamide, or aminoglutethimide. 7. The method of claim 1, wherein said composition is administered orally. 8. The method of claim 1, wherein said composition is administered parenterally. 9. The method of claim 1, wherein said cancer is selected from the group consisting of primary and metastatic malignant solid tumor disease and hematological malignancy. 10. The method of claim 9, wherein said hematological malignancy is selected from the group consisting of acute and chronic myelogenous leukemia, acute and chronic lymphatic leukemia, multiple myeloma, Waldenstrom's macroglobulinemia, hairy cell leukemia, myelodysplastic syndrome, polycythaemia vera, and essential thrombocytosis. 11. The method of claim 1, wherein said composition is formulated for oral administration. 12. The method of claim 1, further comprising administering a therapeutic agent to the subject. 13. The method of claim 1, wherein said subject is a mammal. 14. The method of claim 13, wherein said mammal is a human. 15. The method of claim 1, wherein the therapeutic agent is an antibacterial, an antifungal, an anti-histamine, protein, enzyme, vitamin, hormone, non-steroidal anti-inflammatory, an immune-stimulatory compound, or a steroid. 16. The method of claim 1, wherein the compound is administered at a dose of about 0.5 mg/kg to about 1 g/kg. 17. The method of claim 1, wherein the compound is administered at a dose of about 2 mg/kg to about 4 g/kg.

Details for Patent 10,016,385

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2024-12-17